Table 1

Maneuvers evaluated for measuring performance in chronic disease management: 1 point was awarded for each maneuver performed (0.5 points were awarded if HbA1c was measured only once in the past y).

CAD1,2Recommended aspirinA
Recommended β-blockersA
Recommended statins§Ungraded
Diabetes3,4Recommended ACE inhibitor|| or ARBA, A
HbA1c measured at least twice in past yD
Feet examined in the previous 2 yB
Eyes examined in the previous 2 yB
CHF5,6Recommended ACE inhibitor or ARBA, B
Recommended β-blockersA
COPD7Influenza immunization in the previous 15 moA
Pneumococcal vaccine in the previous 10 yC
Recommended bronchodilatorsA
  • ACE–angiotensin-converting enzyme, ARB–angiotensin receptor blocker, CAD–coronary artery disease, CHF–congestive heart failure, COPD–chronic obstructive pulmonary disease, HbA1c–hemoglobin A1c.

  • * For all medications a minimum of 5 y from the date of evaluation were reviewed for any evidence of recommendation of medication.

  • Aspirin, acetylsalicylic acid, Entrophen, Novasen, enteric-coated acetylsalicylic acid.

  • Sectral, Monitan, Tenormin, Novo-Atenol, Apo-Atenol, Kerlone, Zebeta, Monocor, Cartrol, Coreg, Trandate, Normodyne, Lopresor, Novo-Metoprol, Betaloc, Apo-Metoprolol, Toprol-XL, Corgard, Trasicor, Levatol, Visken, Novo-Pindol, Inderal, Inderal-LA, Apo-Propranolol, Sotacor, Blocadren, Novo-Timol, Apo-Timol.

  • § Lovastatin, pravastatin sodium, lovastatin and niacin, simvastatin, fluvastatin sodium, atorvastatin calcium, rosuvastatin, cerivastatin.

  • || Benazepril, captopril, enalapril, fosinopril, lisinopril, trandolapril, quinapril, quinapril and hydrochlorothiazide, moexipril, cilazapril, ramipril, perindopril.

  • Losartan, losartan and hydrochlorothiazide, irbesartan, irbesartan and hydrochlorothiazide, valsartan, valsartan and hydrochlorothiazide, candesartan cilexetil, cilexetil and hydrochlorothiazide, eprosartan, eprosartan and hydrochlorothiazide, telmisartan, telmisartan and hydrochlorothiazide, olmesartan.